Search Results - "Fagan, Anne M"

ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy by Shi, Yang, Yamada, Kaoru, Liddelow, Shane Antony, Smith, Scott T., Zhao, Lingzhi, Luo, Wenjie, Tsai, Richard M., Spina, Salvatore, Grinberg, Lea T., Rojas, Julio C., Gallardo, Gilbert, Wang, Kairuo, Roh, Joseph, Robinson, Grace, Finn, Mary Beth, Jiang, Hong, Sullivan, Patrick M., Baufeld, Caroline, Wood, Michael W., Sutphen, Courtney, McCue, Lena, Xiong, Chengjie, Del-Aguila, Jorge L., Morris, John C., Cruchaga, Carlos, Fagan, Anne M., Miller, Bruce L., Boxer, Adam L., Seeley, William W., Butovsky, Oleg, Barres, Ben A., Paul, Steven M., Holtzman, David M.

“…ApoE4 exacerbates tau pathogenesis, neuroinflammation and tau-mediated neurodegeneration independently of brain amyloid-β pathology, and exerts a ‘toxic’ gain…”
Get full text

Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction by Nation, Daniel A., Sweeney, Melanie D., Montagne, Axel, Sagare, Abhay P., D’Orazio, Lina M., Pachicano, Maricarmen, Sepehrband, Farshid, Nelson, Amy R., Buennagel, David P., Harrington, Michael G., Benzinger, Tammie L. S., Fagan, Anne M., Ringman, John M., Schneider, Lon S., Morris, John C., Chui, Helena C., Law, Meng, Toga, Arthur W., Zlokovic, Berislav V.

“…Vascular contributions to cognitive impairment are increasingly recognized 1 – 5 as shown by neuropathological 6 , 7 , neuroimaging 4 , 8 – 11 , and…”
Get full text

Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study by Vos, Stephanie JB, MSc, Xiong, Chengjie, Prof, Visser, Pieter Jelle, MD, Jasielec, Mateusz S, MS, Hassenstab, Jason, PhD, Grant, Elizabeth A, PhD, Cairns, Nigel J, Prof, Morris, John C, Prof, Holtzman, David M, Prof, Fagan, Anne M, Prof

“…Summary Background New research criteria for preclinical Alzheimer's disease have been proposed, which include stages for cognitively normal individuals with…”
Get full text

Assessment of Racial Disparities in Biomarkers for Alzheimer Disease by Morris, John C, Schindler, Suzanne E, McCue, Lena M, Moulder, Krista L, Benzinger, Tammie L S, Cruchaga, Carlos, Fagan, Anne M, Grant, Elizabeth, Gordon, Brian A, Holtzman, David M, Xiong, Chengjie

“…Racial differences in molecular biomarkers for Alzheimer disease may suggest race-dependent biological mechanisms. To ascertain whether there are racial…”
Get more information

Current state of Alzheimer’s fluid biomarkers by Molinuevo, José Luis, Ayton, Scott, Batrla, Richard, Bednar, Martin M., Bittner, Tobias, Cummings, Jeffrey, Fagan, Anne M., Hampel, Harald, Mielke, Michelle M., Mikulskis, Alvydas, O’Bryant, Sid, Scheltens, Philip, Sevigny, Jeffrey, Shaw, Leslie M., Soares, Holly D., Tong, Gary, Trojanowski, John Q., Zetterberg, Henrik, Blennow, Kaj

“…Alzheimer’s disease (AD) is a progressive neurodegenerative disease with a complex and heterogeneous pathophysiology. The number of people living with AD is…”
Get full text

Sleep quality and preclinical Alzheimer disease by Ju, Yo-El S, McLeland, Jennifer S, Toedebusch, Cristina D, Xiong, Chengjie, Fagan, Anne M, Duntley, Stephen P, Morris, John C, Holtzman, David M

“…Sleep and circadian problems are very common in Alzheimer disease (AD). Recent animal studies suggest a bidirectional relationship between sleep and β-amyloid…”
Get more information

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease by Blennow, Kaj, Dubois, Bruno, Fagan, Anne M, Lewczuk, Piotr, de Leon, Mony J, Hampel, Harald

“…Abstract Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show any effect on disease progression in clinical trials,…”
Get full text

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury by Suárez-Calvet, Marc, Araque Caballero, Miguel Ángel, Kleinberger, Gernot, Bateman, Randall J, Fagan, Anne M, Morris, John C, Levin, Johannes, Danek, Adrian, Ewers, Michael, Haass, Christian

“…Emerging evidence supports a role for innate immunity and microglia in Alzheimer's disease (AD) pathophysiology. However, no marker related to microglia has…”
Get more information

Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease by Tarawneh, Rawan, D'Angelo, Gina, Crimmins, Dan, Herries, Elizabeth, Griest, Terry, Fagan, Anne M, Zipfel, Gregory J, Ladenson, Jack H, Morris, John C, Holtzman, David M

“…Synaptic loss is an early pathologic substrate of Alzheimer disease (AD). Neurogranin is a postsynaptic neuronal protein that has demonstrated utility as a…”
Get more information

Functional connectivity and graph theory in preclinical Alzheimer's disease by Brier, Matthew R, Thomas, Jewell B, Fagan, Anne M, Hassenstab, Jason, Holtzman, David M, Benzinger, Tammie L, Morris, John C, Ances, Beau M

“…Abstract Alzheimer's disease (AD) has a long preclinical phase in which amyloid and tau cerebral pathology accumulate without producing cognitive symptoms…”
Get full text

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging by Schindler, Suzanne E., Gray, Julia D., Gordon, Brian A., Xiong, Chengjie, Batrla-Utermann, Richard, Quan, Marian, Wahl, Simone, Benzinger, Tammie L.S., Holtzman, David M., Morris, John C., Fagan, Anne M.

“…Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease,…”
Get full text

Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders by Yang, Chengran, Farias, Fabiana H. G., Ibanez, Laura, Suhy, Adam, Sadler, Brooke, Fernandez, Maria Victoria, Wang, Fengxian, Bradley, Joseph L., Eiffert, Brett, Bahena, Jorge A., Budde, John P., Li, Zeran, Dube, Umber, Sung, Yun Ju, Mihindukulasuriya, Kathie A., Morris, John C., Fagan, Anne M., Perrin, Richard J., Benitez, Bruno A., Rhinn, Herve, Harari, Oscar, Cruchaga, Carlos

“…Understanding the tissue-specific genetic controls of protein levels is essential to uncover mechanisms of post-transcriptional gene regulation. In this study,…”
Get full text

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease by Sutphen, Courtney L., McCue, Lena, Herries, Elizabeth M., Xiong, Chengjie, Ladenson, Jack H., Holtzman, David M., Fagan, Anne M.

“…Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition…”
Get full text

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model by Bateman, Randall J, Benzinger, Tammie L, Berry, Scott, Clifford, David B, Duggan, Cynthia, Fagan, Anne M, Fanning, Kathleen, Farlow, Martin R, Hassenstab, Jason, McDade, Eric M, Mills, Susan, Paumier, Katrina, Quintana, Melanie, Salloway, Stephen P, Santacruz, Anna, Schneider, Lon S, Wang, Guoqiao, Xiong, Chengjie

“…Abstract Introduction The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or…”
Get full text

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease by Kester, Maartje I, Teunissen, Charlotte E, Crimmins, Daniel L, Herries, Elizabeth M, Ladenson, Jack H, Scheltens, Philip, van der Flier, Wiesje M, Morris, John C, Holtzman, David M, Fagan, Anne M

“…Neurogranin (NGRN) seems to be a promising novel cerebrospinal fluid (CSF) biomarker for synaptic loss; however, clinical, and especially longitudinal, data…”
Get more information

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging by Gordon, Brian A, Friedrichsen, Karl, Brier, Matthew, Blazey, Tyler, Su, Yi, Christensen, Jon, Aldea, Patricia, McConathy, Jonathan, Holtzman, David M, Cairns, Nigel J, Morris, John C, Fagan, Anne M, Ances, Beau M, Benzinger, Tammie L S

“…The two primary molecular pathologies in Alzheimer's disease are amyloid-β plaques and tau-immunoreactive neurofibrillary tangles. Investigations into these…”
Get full text

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease by Araque Caballero, Miguel Ángel, Suárez-Calvet, Marc, Duering, Marco, Franzmeier, Nicolai, Benzinger, Tammie, Fagan, Anne M, Bateman, Randall J, Jack, Clifford R, Levin, Johannes, Dichgans, Martin, Jucker, Mathias, Karch, Celeste, Masters, Colin L, Morris, John C, Weiner, Michael, Rossor, Martin, Fox, Nick C, Lee, Jae-Hong, Salloway, Stephen, Danek, Adrian, Goate, Alison, Yakushev, Igor, Hassenstab, Jason, Schofield, Peter R, Haass, Christian, Ewers, Michael

“…See Jacobs and Buckley (doi:10.1093/brain/awy243) for a scientific commentary on this article. Despite the prevalence of white matter alterations in…”
Get full text

Suspected non-Alzheimer disease pathophysiology — concept and controversy by Jack, Clifford R., Knopman, David S., Chételat, Gaël, Dickson, Dennis, Fagan, Anne M., Frisoni, Giovanni B., Jagust, William, Mormino, Elizabeth C., Petersen, Ronald C., Sperling, Reisa A., van der Flier, Wiesje M., Villemagne, Victor L., Visser, Pieter J., Vos, Stephanie J. B.

“…Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in…”
Get full text

Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample by La Joie, Renaud, Bejanin, Alexandre, Fagan, Anne M, Ayakta, Nagehan, Baker, Suzanne L, Bourakova, Viktoriya, Boxer, Adam L, Cha, Jungho, Karydas, Anna, Jerome, Gina, Maass, Anne, Mensing, Ashley, Miller, Zachary A, OʼNeil, James P, Pham, Julie, Rosen, Howard J, Tsai, Richard, Visani, Adrienne V, Miller, Bruce L, Jagust, William J, Rabinovici, Gil D

“…OBJECTIVETo assess the relationships between fluid and imaging biomarkers of tau pathology and compare their diagnostic utility in a clinically heterogeneous…”
Get full text

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age by Sutphen, Courtney L, Jasielec, Mateusz S, Shah, Aarti R, Macy, Elizabeth M, Xiong, Chengjie, Vlassenko, Andrei G, Benzinger, Tammie L S, Stoops, Erik E J, Vanderstichele, Hugo M J, Brix, Britta, Darby, Heather D, Vandijck, Manu L J, Ladenson, Jack H, Morris, John C, Holtzman, David M, Fagan, Anne M

“…Individuals in the presymptomatic stage of Alzheimer disease (AD) are increasingly being targeted for AD secondary prevention trials. How early during the…”
Get more information